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A B S T R A C T
Here, we report the establishment of the human iPS cell line N1-FiPS4F#7 generated from skin cells of a patient
with no rheumatic diseases, thus obtaining an appropriate control iPS cell line for researchers working in the
field of rheumatic diseases. The reprogramming factors Oct4, Sox2, Klf4 and c-Myc were introduced using a non-
integrating reprogramming strategy involving Sendai Virus.
Resource Table:
Unique stem cell line identifier ESi080‐A
Alternative name(s) of stem cell line N1-FiPS4F#7
Institution Instituto de Investigación Biomédica de A
Coruña/Universidade da Coruña
Contact information of distributor Silvia Mª Díaz-Prado.
s.diaz1@udc.es
Type of cell line iPSC
Origin Human
Additional origin info Age: 44 years old.
Sex: Female
Ethnicity if known: Caucasian
Cell Source Dermal fibroblasts
Clonality Clonal
Method of reprogramming Sendai Virus vectors (Cytotune
reprogramming kit, ThermoFhiser Scientific).
Genetic Modification NO
Type of Modification N/A
Associated disease N/A
Gene/locus N/A
Method of modification N/A
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date N/A
Cell line repository/bank N/A
Ethical approval Patient informed consent obtained
Ethics Committee of Research of A Coruña-
Ferrol, Spain (register code 2014/405).
Comisión de Seguimiento y Control de la
Donación de Células y Tejidos Humanos del
Instituto de Salud Carlos III (April 13, 2015).
1. Resource utility
Although iPSC-lines have been generated from patients with rheu-
matic diseases, there is still lack of appropriate control lines generated
from patients with radiographic information regarding principal joints
(knee, hip, hands and/or spine). Therefore, we generated a control iPS
cell line from a donor with no rheumatic diseases, as proved radio-
graphically.
2. Resource details
Dermal fibroblasts were isolated from a skin biopsy of a donor with
nor radiographic signs neither symptoms of rheumatic diseases using a
protocol previously described (Vangipuram et al., 2013). Sufficient
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fibroblasts for reprogramming were obtained after two weeks in culture
and three cell passages. These fibroblasts at the 3rd passage were re-
programmed by using Sendai virus vectors containing the human re-
programming factors Oct4, Sox2, Klf4 and c-Myc following the in-
structions of the manufacturer. One week after reprogramming, we
found several tight, small cell colonies in feeder-culture that grew
quickly and, by day 22 after transduction, showed the typical human
ESC-like morphology (Fig. 1 and Table 1), which means compact co-
lonies with defined borders, high nucleus to cytoplasm ratio and pro-
minent nucleoli (Marti et al., 2013). When we picked 10 of these ESC-
like colonies and passaged the fragments onto fresh feeder cells, most of
these subcultures (clones) gave rise to new ESC-like colonies, which
Fig. 1.
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showed positivity for alkaline phosphatase activity (AP) (Fig. 1). The
clearance of the virus and the exogenous reprogramming factor genes
were confirmed by quantitative real time PCR (qRT-PCR) after ten cell
culture passages. The endogenous expression of the pluripotency asso-
ciated transcription factors OCT4, SOX2, KLF4, NANOG and CRIPTO as
well as c-MYC was also evaluated by qRT-PCR (Fig. 1 and Table 1).
According to these above-mentioned parameters all together with the
low expression levels of c-MYC, one clone was selected to establish the
iPS cell line. We confirmed by DNA fingerprinting analysis that the
selected line shared identity with parental fibroblasts (Fig. 1 and
Table 1). Immunofluorescence analysis showed that the line is positive
for the intracellular self-renewal makers NANOG, OCT4 and SOX2, and
the surface pluripotency-related markers SSEA-3, SSEA-4, TRA-1-60
and TRA-1-81 (Fig. 1 and Table 1). The differentiation potential of the
selected iPS cell line was confirmed according to the immuno-
fluorescence-based detection of the endoderm marker alpha-Fetopro-
tein (AFP), the mesoderm marker smooth muscle actin (SMA) and the
ectoderm marker beta-Tubulin III (TUJ1) (Fig. 1) after the pluripotent
differentiation protocols based on embryoid bodies (EBs) formation.
Interestingly, after 2–3 weeks of mesodermal differentiation, sponta-
neously beating cardiomyocytes were observed in cell culture dishes.
The selected line has been adapted to feeder-free culture conditions and
karyotype has been checked, showing a partial mosaic chromosomal
gain on chromosome 5 in ~40% of the cells at passage 63 (Fig. 1, red
arrow and suppl figure 2 and Table 1). Absence of mycoplasma con-
tamination was checked regularly by PCR (suppl Fig. 1 and Table 1).
3. Materials and methods
3.1. Isolation and characterization of dermal fibroblasts
A 44 years old woman with no symptoms of rheumatic diseases was
selected for the study. Absence of joint damage was confirmed radio-
graphically in hip, knee, hand and spine. Dermal fibroblasts were ob-
tained from a skin biopsy as previously described (Vangipuram et al.,
2013).
3.2. Non-integrative reprogramming of fibroblasts
The reprogramming process was conducted introducing the factors
Oct4, Sox2, Klf4 and c-Myc (CytoTune-iPS Sendai reprogramming Kit;
ThermoFisher Scientific) in patient's fibroblasts at the 3rd passage.
Colonies were cultured onto feeder cells (75 Gy-γ-irradiated human
foreskin fibroblasts; HFF-1, ATCC) and using hES culture medium
[DMEM Knockout without L-glutamine, 20% knockout serum replace-
ment, 1% MEM non-essential aminoacids, 1% Glutamax 100X, 1%
Penicilin/Steptomicin, 0.1 mM β-mercaptoethanol and 100 μg/ml basic
fibroblast growth factor (all from Gibco)], which was changed daily.
Cells were kept at 37 °C in a humidified atmosphere with 5% CO2. The
clonal iPS cell line was established by manually picking human ESC-like
colonies. Subsequently, iPS cell clones in passages 10–20 were adapted
and cultured in feeder-free conditions on rh-laminin-521 with Stemflex
medium (all from Gibco). The first 3-4 passages were performed
manually as described above. Further cell propagation was performed
with Versene solution 1X (Gibco).
3.3. Alkaline phosphatase analysis
The iPS cell line N1-FiPS4F#7 with more than twenty passages was
seeded on a feeder layer plate. When colonies appeared, AP activity was
studied using alkaline phosphatase blue membrane substrate solution
kit (AB03000, Sigma-Aldrich).
3.4. RNA extraction and qRT-PCR analyses
Total RNA from parental fibroblasts at the 4th passage, the iPS cell line
at the 10th passage, and parental fibroblasts immediately after repro-
gramming (positive control for Sendai virus) was extracted using the
RNeasy Mini Kit (Qiagen). cDNA synthesis was performed using
SuperScriptTM ViloTM master mix (ThermoFisher Scientific). Expression
levels of the endogenous pluripotency associated genes (OCT4, SOX2, KLF4,
NANOG and CRIPTO), the oncogene c-MYC, and the silencing of the exo-
genous reprogramming factor genes and Sendai virus genome were ana-
lyzed, in duplicate, by qRT-PCR on the LightCycler 480 Instrument (Roche)
using LightCycler 480 SYBR Green I Master (Roche). Primers used for the
amplification were previously described (Aasen et al., 2008).
3.5. EB formation and in vitro differentiation
Pluripotent differentiation assay was performed through the EB
formation protocol. For EB formation, hanging drop method was used
(Vangipuram et al., 2013). After 48h, formed EBs were transferred in-
dependently to 0.1% gelatin (Millipore)-coated 8 well chamber-slides
(Merk), and cultured at 37 °C in a humidified atmosphere with 5% CO2
and in specific differentiation media (Galera et al., 2016) to stimulate
differentiation towards endodermal, mesodermal and ectodermal
lineages.
3.6. Immunofluorescence analyses
Undifferentiated iPS cells at passages 40–60, and cells sprouted
from EBs during pluripotent differentiation were fixed, and immuno-
fluorescence was performed as previously described (Borestrom et al.,
2014). Antibodies used are listed in Table 2.
Table 1
Characterization and validation.
Classification Test Result Data




Cells showed positive staining of pluripotency markers: NANOG, OCT4, SOX2,
SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81
Fig. 1 panel D
Quantitative analysis (RT-qPCR) Cells showed expression of endogenous reprogramming factors OCT4, SOX2, KLF4
and pluripotency markers CRIPTO and NANOG. C-MYC expression was low.
Fig. 1 panel B
Genotype KaryoStatTM assay by ThermoFhiser
Scientific
Partial mosaic chromosomal gain on chromosome 5 in ~40% of the cells at
passage 63. Resolution: gains >2 Mb, losses >1 Mb, absence of
heterozygosity >5 Mb.
Fig. 1 panel F
Identity STR analysis The studied short tandem repeat locations were: D5S818, D13S317, D7S820,
D16S539, VWA, TH01, AMELOGENIN, TPOX, CSF and D21S11. iPS cell line shares
identity with parental fibroblasts.
Fig. 1 panel C
Microbiology and
virology
Mycoplasma Mycoplasma tested by PCR. Negative Fig. 1, supplementary
Differentiation potential Embryoid body formation Sprouted cells from EBs showed positivity for muscle actin, β-tubulin and α-
fetoprotein.
Fig. 1 panel D
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3.7. Karyotype analysis, authentication and mycoplasma testing
Karyotype analysis of the iPS cell line at passage 63 was conducted
by using the KaryoStatTM service (ThermoFisher Scientific), which al-
lows for digital visualization of chromosome aberrations.
For STR evaluation, genomic DNA was extracted from the iPS line
and parental fibroblasts using the DNeasy Blood and Tissue Kit
(Qiagen), and sent to the genomic service at the Alberto Sols Institute of
Biomedical Research for analysis.
Absence of mycoplasma contamination in the iPSCs was checked by
the Genomic platform of the Instituto de Investigación Biomédica de A
Coruña. (Table 1).
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Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-NANOG 1:100 Abcam Cat# ab109250, RRID: AB_10863442
Mouse anti-Oct-3/4 1:50 Santa Cruz Biotechnology Cat# sc- 5279, RRID: AB_628051
Mouse anti-Sox-2 1:500 Santa Cruz Biotechnology Cat# sc-365823, RRID:
AB_10842165
Mouse anti-SSEA-4 1:500 Santa Cruz Biotechnology Cat# sc-21704, RRID: AB_628289
Rat anti-SSEA-3 1:500 Invitrogen Cat# MA1-020, RRID: AB_2536682
Mouse anti-TRA-1-60 1:100 Invitrogen Cat#MA1-023, RRID: AB_2536699
Mouse anti-TRA-1-81 1:100 Abcam Cat# ab16289, RRID: AB_2165986
Differentiation Markers Rabbit anti-alpha 1 fetoprotein 1:500 Abcam Cat# ab46799, RRID: AB_867622
Mouse anti-alpha smooth muscle actin 1:100 Abcam Cat# ab7817, RRID: AB_262054
Mouse anti-beta-Tubulin III 1:500 Sigma-Aldrich Cat# T8660, RRID: AB_477590
Secondary antibodies
Goat anti-rabbit IgG-PE 1:200 Santa Cruz Biotechnology Cat# sc-3739, RRID: AB_649004
Rabbit Anti-Mouse Immunoglobulins, FITC
Conjugated
1:200 Agilent Cat# F031302, RRID: AB_578651
Goat anti-rat IgG, Alexa Fluor 568 Conjugated 1:200 Thermo Fisher Scientific Cat# A-11077, RRID: AB_2534121
Primers
Target Forward/Reverse primer (5′-3′)
Sendai virus vector (qPCR) OCT4 Sendai virus CCCGAAAGAGAAAGCGAACCAG/ AATGTATCGAAGGTGCTCAA
SOX2 Sendai virus ATGCACCGCTACGACGTGAGCGC/ AATGTATCGAAGGTGCTCAA
KLF4 Sendai virus TTCCTGCATGCCAGAGGAGCCC/ AATGTATCGAAGGTGCTCAA
C-MYC Sendai virus TAACTGACTAGCAGGCTTGTCG/ TCCACATACAGTCCTGGATGATGATG
Sendai virus TGGTGCATTTTCGGTTGTTG/ ACCAGACAAGAGTTTAAGA




Pluripotency markers (qPCR) CRIPTO CGGAACTGTGAGCACGATGT/ GGGCAGCCAAGGTGTCATG
NANOG ACAACTGGCCGAAGAATAG/ GGTTCCCAGTCGGGTTCAC
Housekeeping gene (qPCR) GAPDH GCACCGTCAAGGCTGAGAAC/ AGGGATCTCGCTCCTGGAA
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